CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...
Wondering if CRISPR Therapeutics at around US$51.22 is pricing in too much hope or leaving room on the table? This article walks through what the current share price may be implying about the company.
UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...
CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...
Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results